Furthermore, genetic ablation of PARP1 or administration of a PARP1 inhibitor (e.g., PJ-34 and TIQ-A) to ApoE-/- mice, led to decreased atherosclerosis [10–12], which suggests an atherogenic role for PARP1. The gene discussed is PARP1; the disease is atherosclerosis.